Overview

A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)

Status:
Completed
Trial end date:
2014-03-18
Target enrollment:
Participant gender:
Summary
In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial Cystitis.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Europe B.V.